Regulator Missing in Prostate Cancer
By Biotechdaily staff writers
Posted on 26 Jun 2003
Researchers have found that the angiogenesis inhibitor, pigment epithelium–derived factor (PEDF), is a key inhibitor of blood vessel development and epithelial tissue growth in mouse prostate and pancreas. Posted on 26 Jun 2003
Investigators from Northwestern University (Evanston, IL, USA) found that mice lacking PEDF developed an enlarged prostate, resembling human benign prostatic hyperplasia. In a study published in the June 2003 issue of Nature Medicine, they report that PEDF was present in healthy prostate tissue and normal prostate cells, but that little or no PEDF was present in prostate cancer tissue or in isolated prostate cancer cells grown in tissue culture. They found that adding purified PEDF to cultured prostate cancer cells triggered an increased rate of prostate cancer cell death. This effect was enhanced when the cells were deprived of oxygen.
Androgen ablation therapy is an important aspect of prostate cancer treatment. The current study found that this treatment activated PEDF in the cancerous tissue, closed down synthesis of new blood vessels, and led to death of tumor cells.
Related Links:
Northwestern University
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
All-in-One Molecular System
AIO M160
